Soligenix (SNGX) Operating Leases (2019 - 2026)

Soligenix's (SNGX) quarterly Operating Leases came in at $213425.0 in Q1 2026, down 12.57% on a QoQ basis from $244121.0 in Q4 2025.

Soligenix (SNGX) Operating Leases (2019 - 2026) Analysis & Trends

Soligenix (SNGX) has 8 years of Operating Leases data on file, last reported at $213425.0 in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $213425.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $213425.0 (changed N/A YoY) and the FY2025 annual result came in at $244121.0, changed N/A from the prior year.
Operating Leases eased to $213425.0 in Q1 2026, from $244121.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $368282.0 in Q3 2022 to a low of $11544.0 in Q3 2024.
A 5-year average of $192564.2 and a median of $208846.5 in 2023 frame the typical range for Operating Leases.
Annual changes were most pronounced in 2024 — Operating Leases slumped 91.96% — and 2025, when it soared 2272.83%.
Tracing SNGX's Operating Leases over 5 years: stood at $233627.0 in 2022, then slumped by 52.12% to $111862.0 in 2023, then slumped by 89.68% to $11544.0 in 2024, then jumped by 2014.7% to $244121.0 in 2025, then fell by 12.57% to $213425.0 in 2026.
The last three Operating Leases figures came in at $213425.0 (Q1 2026), $244121.0 (Q4 2025), and $273920.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.80 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.53 Bn	3.93 Bn
3	Argenx Se	65.33 Bn	60.14 Bn	1.37 Bn
4	Moderna	59.76 Bn	54.62 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.84 Bn	28.53 Bn	992.69 Mn
7	BioNTech SE	28.23 Bn	9.84 Bn	668.28 Mn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.46 Bn	-
10	Soligenix	6.34 Mn	6.34 Mn	-

Download Data